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Treatment of macrophages with lipopolysaccharide
(LPS) from Gram-negative bacteria or peptidoglycan
(PGN) from Gram-positive bacteria activates multiple
intracellular signaling pathways and a large, diverse
group of nuclear transcription factors. The signaling
receptors for PGN and LPS are now known to be the
Toll-like receptors 2 and 4 (TLR2 and -4, respectively).
While a large body of literature indicates that the mem-
bers of the TLR family activate nearly identical cyto-
plasmic signaling programs, several recent reports have
suggested that the functional outcomes of signaling via
TLR2 or TLR4 are not equivalent. In the current studies,
we compared the responses of the secretory IL-1 recep-
tor antagonist (sIL-1Ra) gene to both LPS and PGN.
Both LPS and PGN induced IL-1Ra gene expression;
however, the combination of both stimuli synergisti-
cally increased sIL-1Ra mRNA expression and promoter
activity, suggesting that the signals induced by PGN and
LPS are not equivalent. While both LPS and PGN uti-
lized the PU.1-binding sites in the proximal sIL-1Ra pro-
moter region to generate a full response, additional dis-
tinct promoter elements were utilized by LPS or PGN.
Activation of p38 stress-activated protein kinase was
required for LPS- or PGN-induced IL-1Ra gene expres-
sion, but the p38-responsive promoter elements local-
ized to distinct regions of the sIL-1Ra gene. Addition-
ally, while the LPS-induced, p38-dependent response
was dependent upon PU.1 binding, the PGN-induced,
p38 response was not. Collectively, these data indicated
that while some of the intracellular signaling events by
TLR2 and TLR4 agonists are similar, there are clearly
distinct differences in the responses elicited by these
two bacterial products.
The molecular mechanisms involved in the regulation of
cytokine genes in macrophages and monocytes in response to
stimulation with bacterial products has been a topic of intense
interest. Treatment of monocytes and macrophages with li-
popolysaccharide from Gram-negative bacteria or peptidogly-
can from Gram-positive bacteria leads to the production of a
vast array of cytokines and chemokines (1) and activates mul-
tiple intracellular signaling pathways including the extracel-
lular signal-regulated kinase, c-Jun N-terminal kinase, and
p38 mitogen-activated protein kinase families (2). Likewise, a
large and diverse group of nuclear transcription factors are also
activated, including NF-B, AP-1, PU.1, and interferon regu-
latory factors (2). In the past few years, our understanding of
the events occurring following the interaction of microbes with
cells of the innate immune response has expanded remarkably.
The Toll-like receptors (TLRs)1 are an evolutionarily con-
served family of cell surface molecules that participate in in-
nate immune recognition of pathogen-associated molecular
patterns (PAMPs) (3). PAMPs are generally unique, chemically
diverse products with conserved motifs that are produced by
microorganisms. PAMPs often have an essential role in the
structure of bacteria and generally cannot be subtly modified
as a result of mutation. Examples include LPS (specifically
lipid A), peptidoglycan (PGN), lipoproteins, bacterial DNA, and
bacterial flagella. At least nine different TLRs have been iden-
tified. In some cases, the bacterial ligand has also been identi-
fied. For example, TLR2 recognizes peptidoglycan (4) and my-
cobacterial lipoarabinomannan (5), TLR4 recognizes LPS from
most Gram-negative species, TLR5 reacts with flagellin (6),
and TLR9 is a receptor for bacterial CpG DNA (7).
The signaling events occurring downstream of the TLRs are
rapidly being elucidated and appear to have many common
features. In general, the cascade of events occurring following
ligation of the different TLRs involves the activation of a com-
mon set of adapter proteins and protein kinases, the best char-
acterized of which leads to the activation of NF-B (reviewed in
(8). Whereas a large body of literature indicates that the mem-
bers of the TLR family activate a nearly identical intracyto-
plasmic signaling program, several recent reports have begun
to suggest that the functional outcomes of signaling via TLR2
or TLR4 are not equivalent. As early as 1996, Dziarski et al. (9)
demonstrated that stimulation of RAW 264.7 macrophages
with LPS or PGN resulted in similar, but not identical activa-
tion of mitogen-activated protein kinases. More recently,
Hirschfeld et al. demonstrated that LPS derived from Porphy-
romonas gingivalis (a TLR2 ligand) or E. coli (a TLR4 ligand)
induced differential expression of a number of genes in murine
macrophages (10). Likewise, Jones, et al. demonstrated that a
secreted TLR2 agonist from culture filtrates of Mycobacterium
tuberculosis and Escherichia coli LPS induced distinct patterns
of cytokine production by RAW 264.7 macrophages (11).
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Interleukin-1 is one of the most highly inflammatory cyto-
kines produced by monocytes/macrophages in response to stim-
ulation with LPS. The discovery of a naturally occurring IL-1
receptor antagonist (IL-1Ra) has suggested a means of modu-
lating the IL-1-induced inflammatory response (12–14). IL-1Ra
is structurally related to IL-1 (13–15) but specifically blocks the
binding of IL-1 and IL-1 to cell surface receptors without
itself activating target cells (16, 17). The term IL-1Ra actually
refers to three closely related proteins. The first form to be
described, secretory or sIL-1Ra, was cloned from IgG-stimu-
lated human monocytes and encodes a protein of 177 amino
acids, including a 25-amino acid hydrophobic leader sequence,
which is subsequently cleaved, resulting in a secreted 152-
amino acid mature protein (14). An alternative form of IL-1Ra,
intracellular or icIL-1Ra, was cloned from an adherent mono-
cyte cDNA library (18). This structural variant is created when
an alternative first exon is spliced into an internal acceptor site
in the first exon of the sIL-1Ra RNA within the region encoding
for the secretory leader sequence. Thus icIL-1Ra is identical to
the mature sIL-1Ra protein except for seven additional amino
acids at the amino-terminal end, and icIL-1Ra lacks the hydro-
phobic leader sequence required for secretion. At the genomic
level, distinct promoters separated by nearly 10 kb of DNA
control the expression of sIL-1Ra and icIL-1Ra. Both forms of
IL-1Ra are equally effective at inhibiting IL-1-induced cellular
responses in vitro. However, given the strictly cell-associated
nature of icIL-1Ra, its role in modulating extracellular inflam-
matory responses remains to be determined. A third, low mo-
lecular weight form of IL-1Ra, termed icIL-1RaII, is derived
from an alternative translation initiation at the second ATG of
either the sIL-1Ra or icIL-1Ra mRNA (19). The biological role
of this form is unknown.
Previously, we have demonstrated that both isoforms of the
human IL-1Ra genes are transcriptionally activated in macro-
phages in response to LPS. Our own studies on the regulation
of the human secretory IL-1Ra promoter have demonstrated
that NF-B, CCAAT/enhancer-binding protein, STAT6, and
most recently PU.1 and GABP are involved in regulating gene
expression in macrophages (20, 21). Of these, PU.1 appears to
be the most critical for the response of the sIL-1Ra gene to LPS.
The response of the sIL-1Ra gene to PGN has not previously
been evaluated. In the current studies, we have compared the
responses of the sIL-1Ra gene to both LPS and PGN. Here we
report that both LPS and PGN can induce sIL-1Ra gene ex-
pression; however, the combination of both stimuli synergisti-
cally up-regulated sIL-1Ra gene expression and promoter ac-
tivity, suggesting that the signals induced by PGN and LPS are
not equivalent. Both LPS and PGN utilized the PU.1-binding
sites in the proximal promoter region to generate a full re-
sponse; however, additional distinct promoter elements were
utilized by LPS or PGN. We determined that the activation of
p38 SAPK was an important component of the response elicited
by LPS and PGN but that the p38-responsive promoter ele-
ments localized to distinct regions of the sIL-1Ra gene. Addi-
tionally, while the LPS-induced p38-dependent response was
dependent upon PU.1 binding, the PGN-induced, p38 response
was not. Collectively, these data indicated that while some of
the intracellular signaling events induced by TLR2 and TLR4
agonists are similar, there are clearly distinct differences in the
responses elicited by these two TLR ligands.
EXPERIMENTAL PROCEDURES
Reagents
LPS (E. coli serotype 055:B5) was obtained from Sigma. Prior to use,
LPS was subjected to an additional purification procedure as described
by Hirschfeld et al. (22). This procedure resulted in LPS that was free
from contaminating endotoxin protein and is a specific TLR4 agonist.
Peptidoglycan purified from Staphyloccous aureus was purchased from
Fluka. The selective p38 inhibitor SB203580 was obtained from Alexis
Pharmaceuticals (San Diego, CA).
Quantitative Real Time Reverse Transcription (RT)-PCR Analysis
Total RNA was purified using the Trizol reagent (Invitrogen).
Briefly, RT of 0.5 g of total cellular RNA was performed in a final
volume of 20 l containing 5 first strand buffer (Invitrogen), 1 mM
concentration of each dNTP, 20 units of placental RNase inhibitor, 5 M
random hexamer, and 9 units of Moloney murine leukemia virus re-
verse transcriptase (Invitrogen). After incubation at 37 °C for 45 min,
the samples were heated for 5 min at 92 °C to end the reaction and
stored at20 °C until PCR use. 2 l of cDNA was subjected to real time,
quantitative PCR using the iCycler (Bio-Rad) with SYBR Green I (Mo-
lecular Probes, Inc., Eugene, OR) as a fluorescent reporter. sIL-1Ra and
GAPDH cDNAs were amplified in separate reactions. Threshold cycle
number was determined using the iCycler software, and levels of sIL-
1Ra expression were normalized to GAPDH levels using the formula
2(Rt  Et), where Rt represents the threshold cycle for the reference gene
(GAPDH) and Et is the threshold cycle for the experimental gene
(sIL-1Ra). Data are thus expressed as arbitrary units. Primer se-
quences were as follows: sIL-1Ra F, AAATCTGCTGGGGACCCTAC;
sIL-1Ra R, TCCCAGATTCTGAAGGCTTG; GAPDH F, GTGTGAACG-
GATTTGGCCGT; GAPDH R, GAGGTCAATGAAGGGGTCGT.
DNA Constructs
Human TLR2, TLR4, and MD-2 Expression Plasmids—Human
TLR2 and TLR4 cDNAs corresponding to the entire coding regions were
generated by RT-PCR using primers corresponding to the published
sequences and cloned into pcDNA3.1Zeo (Invitrogen). The human MD-2
expression construct was generated by RT-PCR and cloned into pEF6/
myc-His (Invitrogen) to generate a molecule containing amino-terminal
c-Myc and His6 tags. Sequences of all clones were confirmed by auto-
mated sequencing.
IL-1Ra Genomic Clone Isolation—A gridded array of P1 clones that
was approximately 2 times representative of the human genome was a
kind gift of Drs. Fiona Watt and Hans Lehrach (Imperial Cancer Re-
search Fund, London, UK). The library was screened by hybridization
with a cDNA probe for exon 2 of human IL1RN, and clone
ICRF700G13105 was identified. The clone contained80 kb of genomic
DNA. DNA was isolated and digested with various rare cutters. BstZI
was used to generate a fragment that contained the entire ILRN gene,
as determined by hybridization with oligonucleotides derived from exon
1 and the 3-end of exon 4. A 23-kb BstZI fragment was subcloned into
a pUC9 derivative that had been modified to replace its linker with a
NotI site containing a stuffer sequence.2 The stuffer sequence was
removed with NotI, and the cohesive BstZI fragments from the P1 clone
were ligated. Recombinant plasmids were screened by hybridization.
Sequencing of the 5-end of the insert indicated that the entire IL1RN
gene was present. This construct was termed pRNZ1.
IL-1Ra Promoter/Luciferase Reporter Constructs—A 7.1-kb sIL-1Ra
promoter/luciferase reporter plasmid was constructed by cloning a
6.8-kb KpnI genomic fragment derived from pRNZ1 into the unique
KpnI site at 294 of the human sIL-1Ra promoter in pA3Luc (20).
Promoter deletions from the 5-end were created by standard subclon-
ing techniques using convenient restriction enzyme sites or PCR. Site-
directed mutants were initially generated in the 294-bp proximal pro-
moter construct by recombinant PCR and verified by sequencing. A
3.1-kb genomic fragment, corresponding to sequences from approxi-
mately 3400 to 294, was subcloned into pBS-SK and then inserted
into the KpnI site as above to generate mutants in the context of the
full-length 3.4-kb sIL-1Ra promoter.
The human CD14 expression vector was a gift of R. Ulevitch (Scripps
Research Institute, La Jolla, CA), and dominant negative MKK3 and
MKK6 plasmids were gifts of R. J. Davis (University of Massachusetts,
Worcester, MA). NF-BLuc was from CLONTECH. All plasmid DNAs
were isolated by using endotoxin-free preparation kits from Qiagen
(Valencia, CA) or Stratagene (La Jolla, CA).
Cell Culture and Transfection
The RAW 264.7 murine macrophage cell line and HEK293 cells were
obtained from ATCC and maintained in RPMI 1640 containing 10%
heat-inactivated fetal bovine serum (Hyclone, Logan, UT). RAW 264.7
cells were cultured and transfected, and luciferase activities were meas-
ured as previously described (21). HEK293 cells were transfected in
2 M. Nicklin, unpublished observations.
Regulation of sIL-1Ra by LPS and PGN 17449
24-well plates using LipofectAMINE (Invitrogen). Each transfection
contained 500 ng of NF-BLuc, 50 ng of TLR2 or TLR4, 50 ng of
pEF6-MD2, 100 ng of pRc/RSVCD14, 200 ng of pTK-renilla (Promega),
and 4 l of LipofectAMINE. Transfections were performed in triplicate,
cultured for 40 h, and then stimulated as indicated for an additional 8 h.
Luciferase activities were determined using the dual luciferase kit from
Promega, and all activities were normalized to the activity of the co-
transfected TK-renilla plasmid.
Western Blot Analysis
Antibodies were obtained as follows: p38 from Santa Cruz Biotech-
nology, Inc. (Santa Cruz, CA); phospho-p38 from New England Biolabs;
and anti-FLAG (M2) from Sigma. For analysis of p38 phosphorylation,
RAW 264.7 cells were seeded into six-well tissue culture plates. Cells
were stimulated for the indicated time with LPS or peptidoglycan,
washed one time with cold phosphate-buffered saline, and lysed in situ
with 100 l of SDS sample buffer. DNA was sheared by passage through
a 25-gauge needle; lysates were boiled for 5 min and iced; and 10 l was
loaded onto a 12.5% SDS-polyacrylamide gel. Separated proteins were
electroblotted unto nitrocellulose, and phosphorylated p38 was detected
with a 1:1000 dilution of the antibody according to the manufacturer’s
recommendation. Detection was carried out using the ECL reagent
from Amersham Biosciences. Blots were stripped of antibodies by wash-
ing in 62.5 mM Tris-HCl (pH 6.7), 100 mM 2-mercaptoethanol, 2% SDS
for 50 min at 50 °C. The filters were then washed in Tris-buffered saline
plus 0.05% Tween 20 and reprobed for total p38.
For detection of FLAG-tagged dominant negative MKK3 or MKK6,
equal amounts of protein from cell lysates of RAW 264.7 cells trans-
fected with expression vectors for the dominant negatives or control
empty vector were immunoprecipitated using the M2 antibody, electro-
phoresed through a 10% SDS-polyacrylamide gel, blotted to nitrocellu-
lose, and detected using the anti-FLAG antibody according to the man-
ufacturer’s recommendations.
RESULTS
Highly Purified LPS and Peptidoglycan Are TLR4- and
TLR2-specific Agonists, Respectively—Hirschfeld et al. (22)
have demonstrated that commercially available preparations
of LPS may be contaminated with endotoxin-associated pro-
teins and as such are not pure TLR4 ligands. In order to
establish that the reagents used in the following studies are
TLR2- and TLR4-specific agonists, we tested their abilities to
activate an NF-B reporter plasmid in HEK293 cells engi-
neered to express either TLR2 or TLR4. We constructed human
TLR2 and TLR4 expression plasmids by cloning the coding
regions for the two genes, generated by RT-PCR from human
monocyte mRNA, into the pcDNA3.1 eukaryotic expression
plasmid (Invitrogen). To validate this system, the experiment
shown in Fig. 1 was performed. HEK293 cells were transiently
transfected with the NF-B/luciferase reporter, Rc/RSV-CD14,
and either pcDNA3-TLR2 or pcDNA3-TLR4. 40 h after trans-
fection, cultures were stimulated for 8 h with the indicated
ligands.
As shown in Fig. 1, unextracted, commercially prepared LPS
and peptidoglycan but not highly purified LPS were able to
activate NF-B in TLR2-transfected cells. In contrast, NF-B
was activated in TLR4-transfected cells by purified or unpuri-
fied LPS but not by peptidoglycan. These results confirmed
that HEK293 cells engineered to express either TLR2 or TLR4
responded appropriately when stimulated with TLR2-specific
(peptidoglycan) or TLR4-specific (repurified E. coli LPS) li-
gands. The dual specificity of the commercially prepared LPS
for TLR2 and TLR4 suggests contamination of the preparations
with endotoxin-associated proteins. However, as predicted, re-
extraction of the LPS according to the previously described
method (22) eliminated signaling via TLR2. These results
therefore confirmed that the LPS and PGN preparations used
in the following studies are pure TLR4 and TLR2 agonists,
respectively.
LPS and Peptidoglycan Induce IL-1Ra Gene Expression—In
earlier studies, we and others have demonstrated that the
human IL-1Ra gene is transcriptionally up-regulated in macro-
phages in response to LPS (20, 24–26). The response of the
IL-1Ra gene to Gram-positive bacterial products has not pre-
viously been examined. In Fig. 2A, we assessed the ability of
LPS, PGN, or the combination to induce sIL-1Ra mRNA in
RAW 264.7 macrophages. Cultures were stimulated for 4 h
with 1 g/ml LPS and/or 10 g/ml PGN, total RNA was puri-
fied, and sIL-1Ra mRNA expression was assessed by quantita-
tive RT-PCR. As expected, treatment with LPS resulted in a
robust enhancement of sIL-1Ra mRNA expression. Peptidogly-
can at 10 g/ml was somewhat less effective in inducing mRNA
expression. Surprisingly, the combination treatment with LPS
and PGN resulted in a very large increase in sIL-1Ra mRNA
expression that was greater than either LPS or PGN alone.
This response occurred despite using quantities of LPS and
PGN that were previously determined to result in maximal
IL-1Ra expression (data not shown).
Previously, we have demonstrated that the proximal 294 bp
of the human sIL-1Ra promoter contained DNA elements re-
quired for the tissue-specific and LPS-inducible activity of the
promoter (21). However, studies in which the -galactosidase
gene was placed under the control of a 1680-bp IL-1Ra pro-
moter fragment and used to create a transgenic mouse demon-
strated that, in fact, this region did not contain all promoter
elements required for appropriate tissue- and stimulus-specific
expression (27). In order to determine whether other, more
distal, cis-acting DNA sequences were contained within the
5-flanking region of the human sIL-1Ra gene, we generated
luciferase reporter constructs containing up to 7100 bp of
sIL-1Ra DNA sequence upstream of the transcriptional start
site. When transfected into RAW 264.7 cells, LPS induced
approximately a 15-fold increase in promoter activity from the
7.1-kb promoter compared with 4-fold from the 294-bp pro-
moter. Furthermore, deletions from the 5-end of this region
demonstrated that the minimal fully LPS- and PGN-responsive
sIL-1Ra promoter consisted of 3400 bp of 5-flanking sequence
(data not shown).
In the experiment shown in Fig. 2B, this 3.4-kb sIL-1Ra
promoter/luciferase reporter construct was transiently trans-
fected in RAW 264.7 cells and the response to LPS, PGN, or the
combination was assessed. Similar to what we observed for
steady state mRNA expression, the human sIL-1Ra promoter
FIG. 1. Highly purified LPS and peptidoglycan are TLR4- and
TLR2-specific agonists, respectively. HEK 293 cells were tran-
siently transfected with NF-BLuc, pRc/RSVCD14, pEF6MD2, and ei-
ther pcDNA3.1-TLR2 or pcDNA3.1-TLR4 plasmids. Triplicate transfec-
tions were stimulated with 1 g/ml LPS or 10 g/ml PGN as indicated
for 8 h prior to assay for luciferase activity as described under “Exper-
imental Procedures.” Data are from a single representative experiment
of three performed.
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was activated approximately equally by LPS or PGN. The
combination of LPS and PGN resulted in a synergistic 37-fold
increase in promoter activity. This result suggested that dis-
tinct signals may be induced by PGN and LPS, which result in
the activation of distinct transcription factors that regulate
IL-1Ra promoter activity.
To determine whether the signals by PGN and LPS do indeed
result in the regulation of IL-1Ra promoter activity through
different cis-acting promoter elements, we assessed the re-
sponses of a series of 5 promoter deletions to LPS or PGN. In
the studies shown in Fig. 3, RAW 264.7 cells were transiently
transfected with human sIL-1Ra promoter constructs ranging
from 294-bp up to 3400 bp, and the activation of each was
determined in response to stimulation of the cells with LPS or
PGN. The results in Fig. 3A indicated the presence of two
previously unidentified LPS-responsive promoter elements:
one between 3.4 and 2.8 kb and a second between 1680
and 294 bp. Fig. 3B shows the results of experiments assess-
ing the response of the same constructs to PGN. In this case,
the PGN response also required sequences between 3.4 and
2.8 kb; however, there was no loss in response when the
region between 1680 and 294 was deleted, suggesting that
this region does not contain promoter sequences required for
the response of the sIL-1Ra promoter to PGN. However, dele-
tion of sequences between 294 and 250 resulted in a de-
crease in the response to PGN without a corresponding loss of
LPS-induced promoter activity. Taken together, these results
indicated that the response of the human sIL-1Ra gene to PGN
or LPS is dependent on the activation of different groups of
transcription factors, the implication of this result being that
the treatment of cells with TLR2 or TLR4 ligands may result in
the activation of different signal transduction programs.
Role of p38 SAPK in LPS- and PGN-induced IL-1Ra Gene
Expression—LPS treatment of macrophages has been demon-
strated to activate multiple mitogen-activated protein kinase
family members including extracellular signal-regulated ki-
nases 1 and 2, c-Jun N-terminal kinase, and p38 (reviewed in
Ref. 28). In addition, Dziarski et al. (9) have demonstrated that
LPS and PGN activate similar but not identical signal trans-
duction pathways in macrophages. In particular, they indi-
cated that p38 SAPK was strongly activated by LPS but only
weakly activated by PGN. In the experiments shown in Fig. 4,
we assessed the activation of p38 in RAW 264.7 cells treated
with LPS and/or PGN using a phospho-p38-specific antibody,
which only recognizes the tyrosine-phosphorylated and hence
activated form of p38. Fig. 4A shows the results of an experi-
ment in which the activation of p38 was assessed following a
10-min stimulation with LPS and/or PGN. Consistent with the
results of Dziarski’s study, we observed that LPS was a stron-
ger activator of p38 than PGN. Additionally, treatment of cells
with a combination of LPS and PGN resulted in a level of p38
phosphorylation that was equivalent to that observed with LPS
alone. To more closely examine the activation of p38 SAPK
following LPS or PGN stimulation, the time course experiment
shown in Fig. 4B was performed. LPS induced a very rapid (5
min) phosphorylation of p38 that was maximal by 15 min and
decreased to a lower steady state level by 45 min. In contrast,
the activation of p38 in response to PGN was reproducibly
delayed by 10–15 min compared with LPS. Similar to LPS,
PGN-activated p38 decreased to a low steady state level, al-
though, like the induction phase of the response, it was also
delayed compared with LPS. Notably, both LPS and PGN were
capable of activating p38 to comparable levels albeit with dif-
ferent kinetics.
In the following studies, we assessed the role of p38 SAPK on
the regulation of sIL-1Ra gene expression in response to PGN
FIG. 2. LPS and PGN induce sIL-1Ra gene expression. A, quan-
titative RT-PCR analysis of sIL-1Ra gene expression in RAW 264.7 cells
stimulated with 1 g/ml LPS, 10 g/ml PGFN, or the combination for
4 h prior to isolation of total cellular RNA. sIL-1Ra mRNA expression
was normalized to GAPDH expression as described under “Experimen-
tal Procedures” and is expressed as arbitrary units. B, RAW 264.7 cells
were transiently transfected with the 3.4-kb IL-1Ra/luciferase reporter
and stimulated for 8 h with LPS, PGN, or the combination of both.
Results indicate relative light units  S.D. of triplicate transfections.
One representative experiment of three performed is shown.
FIG. 3. 5-Deletional mapping of LPS- and PGN-responsive
promoter elements. RAW 264.7 cells were transiently transfected
with luciferase reporter constructs containing human sIL-1Ra promoter
fragments of the indicated length. Cells were stimulated with either 1
g/ml LPS (A) or 10 g/ml PGN (B) for 8 h prior to harvest and assay
for luciferase activity. Results indicate -fold response  S.D. over un-
stimulated cells for each construct. n  4 for each construct. p values
are derived from Student’s t test.
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and LPS. Cultures of RAW 264.7 cells were treated with a 1 M
concentration of the highly selective p38 inhibitor SB203580
for 30 min prior to stimulation with 1 g/ml LPS, 10 g/ml
PGN, or the combination for 4 h. Total RNA was isolated, and
sIL-1Ra mRNA accumulation was analyzed by quantitative
RT-PCR. As shown in Fig. 5A, pretreatment with SB203580
inhibited the accumulation of LPS- or PGN-induced IL-1Ra
mRNA. As demonstrated in Fig. 2, the combination of LPS plus
PGN resulted in a synergistic induction of sIL-1Ra mRNA,
which was also decreased by inhibition of p38. One possible
explanation for this finding is that p38 SAPK affects the sta-
bility of the IL-1Ra mRNA. However, the IL-1Ra mRNA does
not contain the typical AUUUA sequences found in other labile
cytokine mRNAs that are regulated by p38. Thus, we examined
the role of LPS- or PGN-activated p38 in the activation of the
human sIL-1Ra promoter. In the transient transfection exper-
iment shown in Fig. 5B, RAW 264.7 cells were transfected with
the full-length 3.4-kb IL-1Ra promoter/luciferase reporter con-
struct. 30 min prior to stimulation, cultures were treated with
1 M SB203580 followed by stimulation with LPS and/or PGN
for an additional 8 h. Consistent with the results from the
Northern blot experiment, SB203580 was able to inhibit the
activation of the sIL-1Ra promoter in response to LPS, PGN, or
the combination of LPS and PGN. Taken together, these data
indicate that both LPS and PGN regulate sIL-1Ra gene expres-
sion, in part, through the activation of p38 SAPK.
LPS- and PGN-activated p38 Regulate the sIL-1Ra Promoter
through Different Cis-acting Elements—The studies shown in
Fig. 3 indicated that LPS and PGN regulate sIL-1Ra gene
expression through the use of different cis-acting promoter
regions. In the following studies, we sought to determine
whether the responses to LPS-activated and PGN-activated
p38 SAPK map to the same regions within the sIL-1Ra pro-
moter. RAW 264.7 cells were transiently transfected with the
same series of promoter deletion constructs used in the exper-
iments shown in Fig. 3, and the responses to LPS or PGN were
determined in the presence or absence of 1 M SB203580. As
shown in Fig. 6A, the LPS-induced responses of all of the
constructs, with the exception of the 294 promoter, were
decreased as a result of inhibition of p38. This result therefore
indicates that the region of the IL-1Ra promoter between
1680 and 294 contains a p38-responsive cis-acting element
that probably binds transcription factors that are acted upon
either directly or indirectly by p38. This region of DNA contains
putative binding sites for several potential targets of p38 in-
cluding CCAAT/enhancer-binding protein and AP-1. Interest-
ingly, when cloned upstream of a minimal herpes simplex virus
thymidine kinase promoter, the region between 1680 and
294 did not demonstrate any LPS-inducible activity, suggest-
ing that other promoter elements are required for the ability of
these sites to induce sIL-1Ra gene expression (data not shown).
In contrast, the PGN-induced responses of all of the con-
structs, except for the 250 bp promoter construct, were
equally inhibited by SB203580 (Fig. 6B). This result suggests
that the PGN-induced, p38-dependent cis-acting element is
distinct from the LPS-induced element and lies between 294
and250. These surprising results thus suggest that, although
both LPS and PGN activate p38 SAPK, the functional outcomes
of those events are distinct.
LPS and PGN Induce IL-1Ra Expression via MKK3 in RAW
264.7 Macrophages—In order to more closely examine the
mechanism through which LPS and PGN induce IL-1Ra ex-
pression, we sought to determine the roles of MKK3 and MKK6
in activating p38 SAPK and subsequently the IL-1Ra gene. The
following experiments were also undertaken to confirm that
the results with SB203580 were in fact due to its ability to
inhibit p38 and not to due other potential effects such as
inhibition of protein kinase B as previously described (29). To
inhibit activation specifically via MKK3 or MKK6, RAW 264.7
cells were cotransfected with either the 3.4-kb or 294-bp sIL-
FIG. 4. Activation of p38 SAPK by LPS and PGN. RAW 264.7
cells were stimulated with LPS (1 g/ml), PGN (10 g/ml), or the
combination of both for 10 min (A) or for the indicated time (B). Whole
cell lysates were run on a 12% SDS-PAGE gel. Western analysis was
performed using an antibody specific for the phosphorylated form of p38
(pp38). Blots were stripped and reprobed with an antibody that recog-
nizes total p38 (Total p38). Immunoreactive bands were visualized by
chemiluminescence.
FIG. 5. SB203580 inhibits LPS-, PGN-, and LPS plus PGN-in-
duced sIL-1Ra gene expression. A, quantitative RT-PCR analysis of
sIL-1Ra mRNA expression from RAW 264.7 cells that were treated with
1 g/ml LPS, 10 g/ml PGN, or LPS plus PGN for 4 h with or without
a 30-min pretreatment with 1 M SB203580. sIL-1Ra mRNA expression
was normalized to GAPDH expression as described under “Experimen-
tal Procedures” and is expressed as arbitrary units. B, RAW 264.7 cells
were transiently transfected with the 3.4-kb sIL-1Ra promoter/lucifer-
ase reporter construct. Triplicate cultures were treated with LPS, PGN,
or PGN plus LPS for 8 h with or without a 30-min pretreatment with 1
M SB203580. Results are from one representative experiment of three
performed.
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1Ra promoter/luciferase reporter constructs and dominant neg-
ative MKK3 or MKK6 expression plasmids. As shown in Fig.
7A, LPS-induced IL-1Ra promoter activity was inhibited by
cotransfection of dominant negative MKK3 but not MKK6.
This inhibition was equal to that observed when the cells were
treated with SB203580. Consistent with the experiments
shown in Fig. 6, the LPS-induced activity of the 294-bp pro-
moter was not inhibited by dominant negative MKK3 or
MKK6. Likewise, in Fig. 7B we examined the effect of dnMKK3
or dnMKK6 on PGN-induced activity of the 294-bp IL-1Ra
promoter. Again, consistent with results shown in Fig. 6,
dnMKK3 but not dnMKK6 inhibited PGN-induced sIL-1Ra
promoter activity. Immunoprecipitates of lysates from trans-
fected cells using an anti-FLAG antibody demonstrated that
the epitope-tagged MKK3 and MKK6 proteins were in fact both
expressed (Fig. 7C).
Role of PU.1-binding Sites in LPS- and PGN-induced Gene
Expression—The proximal 294-bp sIL-1Ra promoter contains
two PU.1-binding sites that we previously demonstrated to be
critical for the response of the proximal promoter to LPS (21).
One of these sites, located at 81 to 93, is a composite
NF-B/PU.1/GABP binding site. Our earlier studies demon-
strated that GABP did not participate in the LPS response of
the IL-1Ra promoter; however, NF-B and PU.1 did. To assess
the role of PU.1 in regulating the activity of the full-length
sIL-1Ra promoter in response to LPS- and PGN-activated p38,
a series of site-directed mutants at the two proximal PU.1-
binding sites were generated in the context of the 3.4-kb pro-
moter fragment.
As shown in Fig. 8A, mutation of the downstream PU.1/
NF-B site (Fig. 8B) resulted in a loss of LPS responsiveness
that could be further inhibited by SB203580. Likewise, muta-
tion of the upstream PU.1 site located at 225 (C) resulted in
an 40% decrease in the LPS response, consistent with our
previously published studies and was significantly inhibited by
treatment with SB203580. However, mutation of both sites (D)
resulted in a further loss of LPS responsiveness that was not
affected by inhibition of p38. Since the LPS responsive element
between 81 and 93 is a composite NF-B/PU.1-binding site,
we wanted to clarify the role of PU.1 or NF-B in regulating
p38-responsive IL-1Ra promoter activity. Site-directed mu-
tants, in the context of the full-length 3400-bp promoter, were
generated, which contained a mutation within the 225 PU.1
site as well as specifically blocked PU.1 or NF-B binding to the
81 to93 site (21). Mutation of the PU.1 half-site (E) resulted
in a promoter construct with the same functional characteris-
tics as the double mutant: low response to LPS and no inhibi-
tion by SB203580. However, mutation of the NF-B half-site
(F) resulted in a promoter construct with increased LPS re-
sponsiveness that was also inhibited by treatment with
SB203580. Taken together, these results demonstrated that, in
FIG. 6. LPS- and PGN-activated p38 regulate the sIL-1Ra pro-
moter through different cis-acting elements. RAW 264.7 cells were
transiently transfected with the indicated IL-1Ra promoter/luciferase
reporter construct and stimulated with 1 g/ml LPS or 10 g/ml PGN in
the presence or absence of 1 M SB203580 for 8 h. A, -fold response to
LPS  S.D. of at least four transfections with each construct. B, -fold
response to PGN  S.D. of at least four transfections with each con-
struct. C, percent inhibition of the response to LPS or PGN by pretreat-
ment with SB203580. Data represent means  S.D. from at least four
experiments with each construct.
FIG. 7. LPS and PGN induce sIL-1Ra promoter activity via
MKK3. RAW 264.7 cells were transiently transfected with sIL-1Ra
promoter/luciferase reporters and expression vectors for dominant neg-
ative MKK3, MKK6, or empty vector. Cultures were stimulated with 1
g/ml LPS or 10 g/ml PGN for 8 h prior to assay for luciferase activity.
Results are means  S.D. of three separate experiments. p values were
determined by paired t test. A, LPS response. Cells were transfected
with either the 3400- or 294-bp IL-1Ra promoters. B, PGN response.
Cells were transfected with the 294-bp IL-1Ra promoter reporter. C,
immunoblot of whole cell lysates from transfected cells demonstrating
the expression of the FLAG-tagged dominant negative MKK proteins as
described under “Experimental Procedures.”
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the context of the full-length 3.4-kb sIL-1Ra promoter, PU.1
binding is critical for full responsiveness to LPS. Additionally,
the p38-dependent promoter activity also requires PU.1. How-
ever, the ability of PU.1 alone to regulate LPS-inducible ex-
pression of the sIL-1Ra gene does not appear to be directly
dependent on p38, since the LPS response of the intact proxi-
mal 294-bp promoter, which contains both PU.1-binding sites,
was unaffected by treatment with SB203580 (Fig. 6, A and C).
The role of the proximal PU.1 sites in the control of PGN-
induced promoter activity was also examined (Fig. 8B). The
response of the sIL-1Ra promoter to PGN was also dependent
upon the presence of the PU.1 sites; however, this dependence
was clearly less than that of LPS as evidenced when both PU.1
sites are mutated (Fig. 8B, lanes D and E). Mutation of both
PU.1 sites reduced the response of the promoter to LPS by
75%, but the PGN response was only reduced 50%. More
striking was the lack of a requirement for PU.1 in response of
the sIL-1Ra gene to PGN-activated p38. Unlike LPS, which had
an absolute requirement for at least one PU.1-binding site in
order to respond via p38, mutation of the PU.1 sites had no
effect on the ability of SB203580 to inhibit PGN-induced pro-
moter activity. Collectively, these results indicated that 1)
PU.1 is not likely to be a direct target of p38 action; 2) the
transcription factor activated by LPS-induced p38 may require
the presence of PU.1 for its function; and 3) the PGN-induced,
p38-responsive factor works independently of PU.1
DISCUSSION
Over the past few years, our understanding of the molecular
mechanisms involved in the response of cells of the innate
immune system to microbial products has increased dramati-
cally. The identification of mammalian Toll-like receptors as
the cell surface proteins that distinguish between different
bacterial products and transduce signals to the responding cell
was a highly significant finding. Interestingly, although the
different TLRs recognize a wide variety of chemically diverse
bacterial products, most studies have indicated that they acti-
vate a similar series of intracellular signaling molecules (re-
viewed in Ref. 30). Several recent papers have suggested that
the signals generated by TLR2 and TLR4 are not equivalent.
Hirschfeld et al. (10) compared the responses of 11 different
genes in macrophages to LPS derived from E. coli or P. gingi-
valis (TLR4 and TLR2 ligands, respectively). While the induc-
tion of mRNA for genes such as macrophage inflammatory
protein-1 and IL-1 was equivalent for E. coli or P. gingivalis
LPS, other genes such a IL-6 and IL-12p40 were at best only
weakly induced by the TLR2-specific LPS. Likewise, Jones et
al. (11) demonstrated that whereas both LPS and a soluble
TLR2 agonist from culture filtrates of M. tuberculosis (manno-
sylated phophatidylinositol) could induce tumor necrosis fac-
tor- production, only LPS was capable of inducing IL-1 and
nitric oxide secretion. One possible molecular mechanism for
the differential signaling downstream of TLR2 and TLR4 has
been provided by the recent identification of a second, receptor-
proximal adapter protein (in addition to MyD88) that partici-
pates in TLR4 but not TLR2 signaling (31, 32).
In this report, we have provided evidence that different Toll-
like receptor ligands can activate the same gene through dif-
ferent mechanisms. We studied the regulation of the gene for
the secreted IL-1 receptor antagonist in response to the TLR2
agonist PGN and the TLR4 agonist E. coli LPS. While both
PGN and LPS could induce sIL-1Ra gene expression and pro-
moter activity to approximately equal levels, the combination
of the two stimuli resulted in a synergistic increase in both
mRNA accumulation and promoter activity. This result sug-
FIG. 8. Role of PU.1-binding sites in LPS- or PGN-induced sIL-1Ra promoter activity. RAW 264.7 cells were transfected with the
indicated site-directed mutant sIL-1Ra promoter/luciferase reporter. Cultures were stimulated with 1 g/ml LPS or 10 g/ml PGN in the presence
or absence of 1 M SB203580 as described in Fig. 6. Results represent means  S.D. of at least three separate experiments with each construct.
p values were determined by paired t test. A, LPS response. Responses that were not significantly inhibited by SB203580 are indicated. B, PGN
response. The responses of all constructs were significantly inhibited by SB203580 (p  0.05).
Regulation of sIL-1Ra by LPS and PGN17454
gested that stimulation of macrophages with PGN or LPS did
not generate equivalent intracellular signals. These findings
were confirmed when we determined that different regions of
the human sIL-1Ra promoter were required for full responsive-
ness to LPS or PGN. Whereas the responses to both LPS and
PGN required the previously identified PU.1-binding sites in
the proximal promoter region, the response to LPS also utilized
at least two more distally located promoter elements. The re-
sponse to PGN required an additional element within the prox-
imal 300-bp and an additional region located between 3400 and
2800 bp upstream of the transcription start site. The most
distal response element for PGN co-localized with a region
required for full LPS-responsiveness. Although we have not yet
identified the transcription factors that are differentially acti-
vated by LPS and PGN, these are the first studies that we
know of that clearly indicate that activation of macrophages via
LPS and PGN can result in the activation of different DNA-
binding proteins. Studies are currently in progress to defini-
tively identify the transcription factors that are differentially
activated in response to LPS and PGN.
In these studies, we also examined the role of p38 SAPK in
the regulation of IL-1Ra gene expression induced by PGN and
LPS. Treatment of macrophages with either LPS or PGN re-
sulted in the activation of p38 SAPK, albeit with somewhat
different kinetics (Fig. 4). Our results are generally consistent
with those previously published by Dziarski et al. (9), who
demonstrated that LPS was a more potent inducer of p38
activity than PGN. The reason for the delayed activation of p38
in response to PGN is unclear but could relate to receptor
density or the requirement for other TLRs, such as TLR6, to be
recruited into the complex (33).
Northern blot analysis of LPS and/or PGN treated RAW
264.7 cells demonstrated that pretreatment with the p38-in-
hibitory pyridinyl imidazole compound SB203580 resulted in a
decrease in IL-1Ra mRNA expression. The mode of action of
p38 in the regulation of LPS-induced gene expression is very
much gene-dependent. In some instances (e.g. tumor necrosis
factor-, IL-6, and macrophage inflammatory protein-1), in-
hibition of p38 activity was demonstrated to result in acceler-
ated mRNA decay (34). However, inhibition of p38 activity
blocked LPS-induced neuroleukin and interferon-stimulated
gene 15 gene expressions without affecting mRNA stability,
suggesting a role for p38 in the transcriptional regulation of
those genes (35). The ability of p38 to regulate mRNA stability
is likely to relate to the presence of AU-rich elements found
within the 3-untranslated regions of many cytokine genes (34,
36, 37). The sequence of the IL-1Ra 3-untranslated region does
not contain the typical AUUUA sequences found in other labile
cytokine mRNAs that are regulated by p38 and is unlikely to be
regulated by p38-dependent post-transcriptional mechanisms.
This hypothesis was confirmed in transient transfection assays
with IL-1Ra promoter constructs. Similar to the mRNA analy-
sis, pretreatment of RAW 264.7 cells with SB203580 prior to
LPS and/or PGN stimulation significantly inhibited promoter
activity. Thus, both TLR2-induced and TLR4-induced IL-1Ra
expression have as a requirement the activation of p38 SAPK.
Surprisingly, the LPS- and PGN-induced p38 responses
mapped to different regions of the IL-1Ra promoter and dis-
played differing requirements for the previously identified
PU.1-binding sites.
The mechanism through which PU.1 regulates LPS-induci-
ble gene expression is unclear. Earlier studies determined that
PU.1 can be inducibly phosphorylated by casein kinase II in
response to LPS stimulation of macrophages, and this phos-
phorylation appears to be required for the transactivation func-
tion of PU.1 (38). In the studies presented here, the LPS-
responsive 294-bp IL-1Ra promoter, which contains two PU.1-
binding sites, was not sensitive to inhibition of p38 SAPK,
suggesting that PU.1 was not a target of the p38 signaling
cascade. However, the data presented in Fig. 8 indicate that
PU.1 is critical for the ability of the IL-1Ra gene to respond to
LPS-induced p38 SAPK. These data would suggest that a func-
tional interaction of PU.1 with transcription factors that bind
to the distal promoter is critically dependent on the activity of
p38 SAPK. Such a result would be consistent with the notion
that a major role for PU.1 is to recruit other factors into the
transcription complex (39–44). Additionally, these are the first
data indicating a role for PU.1 in the regulation of gene expres-
sion induced by PGN.
The p38 SAPK family contains four distinct isoforms, p38,
p38, p38, and p38; however, only p38 and p38 are sensi-
tive to inhibition by SB203580 (45). The activities of the p38
family members are regulated by phosphorylation of a con-
served TGY motif in kinase subdomain VIII by MKK6 or, with
the exception of p38, by MKK3 (46). Our studies using
SB203580 to inhibit p38 activity therefore indicated that LPS-
or PGN-induced sIL-1Ra gene expression was regulated by
either p38 or p38. In the experiments shown in Fig. 7, we
demonstrated that only MKK3 was involved in the regulation
of IL-1Ra promoter activity. Since MKK3 cannot activate p38,
these results indicate that LPS- or PGN-induced IL-1Ra gene
expression is controlled, at least in part, via the MKK3-depend-
ent activation of p38.
A major question to arise from these studies is: How is it
that, although both LPS and PGN share a common group of
signaling intermediates and indeed are both capable of activat-
ing p38 SAPK, the two stimuli appear to activate different
transcription factors? Given the large number of known TLRs
that respond to a wide variety of ligands and the apparent
similarities in the signaling mechanisms thus far identified for
them, it would seem as if a mechanism would need to be in
place in order for an organism to generate a response appro-
priate for and specific to a given pathogen. At least two differ-
ent mechanisms can be envisioned for this.
One possible explanation is that the TLR2 and TLR4 signal-
ing complexes are ultimately linked to different transcription
factors through as yet unidentified scaffolding proteins. Re-
cently, the role of scaffolding proteins in the control of the
specificity of activation and function of the mitogen-activated
protein kinase modules has been a topic of keen interest (re-
viewed in Refs. 23, 47, and 48). Although a clear demonstration
of a transcription factor being included in a “signalsome” com-
plex has not as yet been provided, such a mechanism cannot as
yet be excluded. Having the different TLRs linked to specific
transcription factors through scaffolding proteins could provide
a mechanism to generate such specificity.
A second and perhaps more plausible explanation may be
that although both receptors activate p38, each activates a
different second signal, and it is the second signal that deter-
mines where the p38 response maps to. The studies reported
herein and in the recent literature (10, 11, 31, 32) clearly
indicate that the signals transmitted via different TLRs are not
equivalent. Thus far, a significant amount of work has focused
on signaling mechanisms that the different TLRs have in com-
mon (e.g. NF-B). These recent studies now indicate that we
need to look more closely at the differences.
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